Search alternatives:
teer decrease » greater decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
teer decrease » greater decrease (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
6201
-
6202
-
6203
-
6204
-
6205
-
6206
-
6207
-
6208
-
6209
-
6210
-
6211
Data_Sheet_1_The Salvinorin Analogue, Ethoxymethyl Ether Salvinorin B, Promotes Remyelination in Preclinical Models of Multiple Sclerosis.PDF
Published 2021“…In the experimental autoimmune encephalomyelitis model, we found that EOM SalB (0.1–0.3 mg/kg) effectively decreased disease severity in a KOR-dependent manner and led to a greater number of animals in recovery compared to U50,488 treatment. …”
-
6212
-
6213
Unusual clinical phenotype of Stargardt disease
Published 2022“…Pattern electroretinogram demonstrated bilateral decrease of p50 values. Genetic testing identified two heterozygous missense mutations, c.428C>T, p.…”
-
6214
Transcriptome-microRNA analysis of <i>Sarcoptes scabiei</i> and host immune response
Published 2017“…<div><p>Scabies is a parasitic disease, caused by the mite <i>Sarcoptes scabiei</i>, and is considered one of the top 50 epidemic diseases and one the most common human skin disease, worldwide. …”
-
6215
-
6216
Protective Effects of Triphala on Dermal Fibroblasts and Human Keratinocytes
Published 2016“…TE also exhibited anti-tyrosinase and melanin inhibition properties in a dose-dependent manner. TE increased the mRNA expression of collagen-I, elastin, superoxide dismutase (SOD-2), aquaporin-3 (AQP-3), filaggrin, involucrin, transglutaminase in HDF or HaCaT cells, and decreased the mRNA levels of tyrosinase in B16F10 cells. …”
-
6217
-
6218
-
6219
-
6220
Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes with Alirocumab: Post-Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial
Published 2025“…<a href="" target="_blank">OR for NOD for 25% and 50% lipoprotein(a) reductions were 1.12 (95% CI 1.01</a>-1.23) and 1.24 (1.02-1.52). …”